Paradigm Biopharmaceuticals Limited

CHIA:PAR Stock Report

Market Cap: AU$131.0m

Paradigm Biopharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

CHIA:PAR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Oct 24BuyAU$50,909Paul RennieIndividual245,300AU$0.21
14 Oct 24BuyAU$73,274Matthew FryIndividual350,000AU$0.21
24 Sep 24SellAU$891,158Allianz Asset Management GmbHCompany3,935,875AU$0.27
17 May 24SellAU$135,591Allianz Asset Management GmbHCompany4,283,087AU$1.42

Insider Trading Volume

Insider Buying: PAR insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of PAR?
Owner TypeNumber of SharesOwnership Percentage
Private Companies17,001,5014.87%
Individual Insiders27,363,4107.83%
Institutions58,130,58516.6%
General Public246,931,52770.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 23 shareholders own 29.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.97%
Allianz Asset Management GmbH
17,372,860AU$6.5m-18.5%no data
4.34%
Collins St Asset Management Pty Ltd
15,148,692AU$5.7m596%3.69%
3.26%
Kzee Pty Ltd
11,380,902AU$4.3m0%no data
2.95%
RBC Global Asset Management Inc.
10,310,378AU$3.9m0%no data
2.67%
Paul Rennie
9,345,848AU$3.5m0.52%no data
2.07%
Netwealth Investments Ltd.
7,233,311AU$2.7m0.47%0.02%
0.99%
Nancy Wilson-Ghosh
3,475,835AU$1.3m0%no data
0.88%
Evan Clucas
3,064,598AU$1.1m91.1%no data
0.88%
Leanne Weston
3,064,597AU$1.1m91.1%no data
0.69%
39KP Pty Ltd
2,427,367AU$910.3k65.2%no data
0.69%
Adam Huts
2,405,000AU$901.9k0%no data
0.67%
Fiftyone Capital Pty Ltd
2,337,318AU$876.5k-41%no data
0.64%
Pictet Asset Management Limited
2,249,331AU$843.5k0%no data
0.59%
Anthony Van Der Steeg
2,051,787AU$769.4k0%no data
0.46%
Juzcorp Pty Limited
1,607,958AU$603.0k0%no data
0.45%
Pershing Securities Australia Pty. Ltd.
1,585,274AU$594.5k0%no data
0.45%
Flinders Medical Centre Foundation
1,562,000AU$585.8k10%100.0%
0.41%
Lingtye Yu
1,441,631AU$540.6k0%no data
0.41%
Matthew Fry
1,419,830AU$532.4k32.7%no data
0.31%
Donna Skerrett
1,094,284AU$410.4k0%no data
0.26%
Pictet Asset Management (Singapore) Pte Ltd
906,940AU$340.1k0%0.27%
0.23%
Australian Super Pty Ltd
804,511AU$301.7k0%no data
0.059%
Dimensional Fund Advisors LP
205,244AU$77.0k0.09%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 15:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Arron AatkarEdison Investment Research